Piramal Pharma jumps as its division launches Chlorpromazine Hydrochloride for Injection, USP
Piramal Pharma is currently trading at Rs. 248.05, up by 5.40 points or 2.23% from its previous closing of Rs. 242.65 on the BSE.
The scrip opened at Rs. 242.70 and has touched a high and low of Rs. 248.65 and Rs. 241.95 respectively. So far 64678 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 307.85 on 06-Nov-2024 and a 52 week low of Rs. 114.45 on 15-Mar-2024.
Last one week high and low of the scrip stood at Rs. 248.65 and Rs. 228.80 respectively. The current market cap of the company is Rs. 32335.00 crore.
The promoters holding in the company stood at 34.95%, while Institutions and Non-Institutions held 45.78% and 19.27% respectively.
Piramal Pharma’s division -- Piramal Critical Care (PCC) has launched Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials. With this launch, PCC continues to expand their generic injectables portfolio.
The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2024, PCC launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
